Octavio Espinoza, CFO of Ligand Pharmaceuticals ($LGND), made two open market purchases totaling $156 thousand in the past year, with the most recent on May 9, 2025. This ranks 1,769th among nearly 5,000 insiders, well below the average of 1.5 million per buyer. He conducted 12 open market sales totaling 3.1 million, most recently on March 4, 2026, ranking 2,654th out of nearly 12,000 insiders versus an average of 8.6 million per seller.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | A | Employee Stock Option (right to buy) | 23527 | $0.00 | 23,527.0000 | 20,629,000 | 9999.99% | 0.11% |
| March 2, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | A | Common Stock | 4933 | $0.00 | 37,945.0000 | 20,629,000 | 14.94% | 0.02% |
| March 11, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 2405 | $92.65 | 24,067.0000 | 20,629,000 | 11.10% | 0.01% |
| March 11, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 3057 | $225.00 | 21,010.0000 | 20,629,000 | 12.70% | 0.01% |
| March 11, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 2405 | $0.00 | 0.0000 | 20,629,000 | 100.00% | 0.01% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 697 | $202.79 | 31,988.0000 | 20,629,000 | 2.13% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 3413 | $208.80 | 21,662.0000 | 20,629,000 | 13.61% | 0.02% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 2457 | $207.91 | 25,075.0000 | 20,629,000 | 8.92% | 0.01% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 1588 | $206.89 | 27,532.0000 | 20,629,000 | 5.45% | 0.01% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 1457 | $205.79 | 29,120.0000 | 20,629,000 | 4.77% | 0.01% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 743 | $204.74 | 30,577.0000 | 20,629,000 | 2.37% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 668 | $203.63 | 31,320.0000 | 20,629,000 | 2.09% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 950 | $201.73 | 32,685.0000 | 20,629,000 | 2.82% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 1607 | $58.49 | 34,619.0000 | 20,629,000 | 4.87% | 0.01% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 466 | $80.72 | 35,085.0000 | 20,629,000 | 1.35% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 699 | $198.71 | 34,386.0000 | 20,629,000 | 1.99% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 53 | $200.08 | 34,333.0000 | 20,629,000 | 0.15% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 698 | $201.09 | 33,635.0000 | 20,629,000 | 2.03% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 466 | $0.00 | 0.0000 | 20,629,000 | 100.00% | 0.00% |
| March 4, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 1607 | $0.00 | 0.0000 | 20,629,000 | 100.00% | 0.01% |
| Feb. 15, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | F | Common Stock | 1223 | $183.83 | 34,282.0000 | 20,629,000 | 3.44% | 0.01% |
| Feb. 15, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | F | Common Stock | 1270 | $183.83 | 33,012.0000 | 20,629,000 | 3.70% | 0.01% |
| Feb. 15, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | F | Common Stock | 1026 | $183.83 | 35,505.0000 | 20,629,000 | 2.81% | 0.00% |
| Feb. 14, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | F | Common Stock | 4483 | $183.83 | 36,531.0000 | 20,629,000 | 10.93% | 0.02% |
| Feb. 14, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | A | Common Stock | 8810 | $0.00 | 41,014.0000 | 20,629,000 | 27.36% | 0.04% |
| Feb. 14, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | F | Common Stock | 3761 | $183.83 | 32,204.0000 | 20,629,000 | 10.46% | 0.02% |
| Feb. 14, 2026 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | A | Common Stock | 7390 | $0.00 | 35,965.0000 | 20,629,000 | 25.86% | 0.04% |
| Dec. 31, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | J | Common Stock | 8 | $95.68 | 28,575.0000 | 20,629,000 | 0.03% | 0.00% |
| Dec. 16, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 285 | $63.62 | 27,734.0000 | 20,629,000 | 1.04% | 0.00% |
| Dec. 16, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 1194 | $0.00 | 972.0000 | 20,629,000 | 55.12% | 0.01% |
| Dec. 16, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 69 | $0.00 | 7,171.0000 | 20,629,000 | 0.95% | 0.00% |
| Dec. 16, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 285 | $0.00 | 18,171.0000 | 20,629,000 | 1.54% | 0.00% |
| Dec. 16, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 652 | $0.00 | 2,405.0000 | 20,629,000 | 21.33% | 0.00% |
| Dec. 16, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 181 | $0.00 | 4,186.0000 | 20,629,000 | 4.14% | 0.00% |
| Dec. 16, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 69 | $57.22 | 27,449.0000 | 20,629,000 | 0.25% | 0.00% |
| Dec. 16, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 1194 | $52.84 | 27,380.0000 | 20,629,000 | 4.56% | 0.01% |
| Dec. 16, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 652 | $92.65 | 28,386.0000 | 20,629,000 | 2.35% | 0.00% |
| Dec. 16, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 181 | $103.42 | 28,567.0000 | 20,629,000 | 0.64% | 0.00% |
| Dec. 12, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 1804 | $188.31 | 26,186.0000 | 20,629,000 | 6.45% | 0.01% |
| Dec. 5, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | F | Common Stock | 1862 | $184.87 | 27,990.0000 | 20,629,000 | 6.24% | 0.01% |
| June 30, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | J | Common Stock | 224 | $91.08 | 29,852.0000 | 18,290,000 | 0.76% | 0.00% |
| May 9, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | P | Common Stock | 1000 | $103.89 | 27,432.0000 | 18,290,000 | 3.78% | 0.01% |
| May 9, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | P | Common Stock | 500 | $104.40 | 27,932.0000 | 18,290,000 | 1.82% | 0.00% |
| March 4, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 5000 | $115.03 | 18,879.0000 | 18,290,000 | 20.94% | 0.03% |
| March 4, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | A | Common Stock | 7484 | $0.00 | 26,363.0000 | 18,290,000 | 39.64% | 0.04% |
| March 4, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | A | Employee Stock Option (right to buy) | 32717 | $0.00 | 32,717.0000 | 18,290,000 | 9999.99% | 0.18% |
| Feb. 15, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | F | Common Stock | 782 | $120.00 | 25,100.0000 | 18,290,000 | 3.02% | 0.00% |
| Feb. 14, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | A | Common Stock | 5429 | $0.00 | 26,076.0000 | 18,290,000 | 26.29% | 0.03% |
| Feb. 14, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | F | Common Stock | 2757 | $120.00 | 23,319.0000 | 18,290,000 | 10.57% | 0.02% |
| Feb. 14, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | A | Common Stock | 7390 | $0.00 | 30,709.0000 | 18,290,000 | 31.69% | 0.04% |
| Feb. 14, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | F | Common Stock | 3803 | $120.00 | 26,906.0000 | 18,290,000 | 12.38% | 0.02% |
| Feb. 15, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | F | Common Stock | 1024 | $120.00 | 25,882.0000 | 18,290,000 | 3.81% | 0.01% |
| Feb. 15, 2025 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | F | Common Stock | 1221 | $120.00 | 23,879.0000 | 18,290,000 | 4.86% | 0.01% |
| Dec. 23, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 2104 | $116.37 | 20,647.0000 | 18,574,000 | 9.25% | 0.01% |
| Dec. 5, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | F | Common Stock | 1859 | $123.51 | 22,751.0000 | 18,574,000 | 7.55% | 0.01% |
| Sept. 20, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 275 | $103.86 | 25,410.0000 | 17,757,000 | 1.07% | 0.00% |
| Sept. 20, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 200 | $103.98 | 25,685.0000 | 17,757,000 | 0.77% | 0.00% |
| Sept. 20, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 800 | $103.95 | 24,610.0000 | 17,757,000 | 3.15% | 0.00% |
| Sept. 17, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 69 | $57.22 | 25,885.0000 | 17,757,000 | 0.27% | 0.00% |
| Sept. 17, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 1417 | $80.72 | 25,816.0000 | 17,757,000 | 5.81% | 0.01% |
| Sept. 17, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 1417 | $0.00 | 466.0000 | 17,757,000 | 75.25% | 0.01% |
| Sept. 17, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 69 | $0.00 | 7,240.0000 | 17,757,000 | 0.94% | 0.00% |
| Aug. 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 207 | $57.22 | 23,853.0000 | 17,757,000 | 0.88% | 0.00% |
| Aug. 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Incentive Stock Option (right to buy) | 546 | $0.00 | 0.0000 | 17,757,000 | 100.00% | 0.00% |
| Aug. 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 207 | $0.00 | 7,309.0000 | 17,757,000 | 2.75% | 0.00% |
| Aug. 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 546 | $70.04 | 24,399.0000 | 17,757,000 | 2.29% | 0.00% |
| June 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | J | Common Stock | 267 | $60.71 | 23,646.0000 | 17,757,000 | 1.14% | 0.00% |
| May 17, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 1544 | $63.62 | 23,368.0000 | 17,757,000 | 7.07% | 0.01% |
| May 17, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Non-Qualified Stock Option (right to buy) | 5022 | $0.00 | 16,179.0000 | 17,757,000 | 23.69% | 0.03% |
| May 17, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Incentive Stock Option (right to buy) | 145 | $0.00 | 0.0000 | 17,757,000 | 100.00% | 0.00% |
| May 17, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 1544 | $0.00 | 18,456.0000 | 17,757,000 | 7.72% | 0.01% |
| May 17, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 206 | $0.00 | 7,516.0000 | 17,757,000 | 2.67% | 0.00% |
| May 17, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 134 | $86.65 | 23,379.0000 | 17,757,000 | 0.57% | 0.00% |
| May 17, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 5022 | $86.67 | 23,513.0000 | 17,757,000 | 17.60% | 0.03% |
| May 17, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 5022 | $52.84 | 28,535.0000 | 17,757,000 | 21.36% | 0.03% |
| May 17, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 145 | $68.74 | 23,513.0000 | 17,757,000 | 0.62% | 0.00% |
| May 17, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 206 | $57.22 | 21,824.0000 | 17,757,000 | 0.95% | 0.00% |
| May 16, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 2264 | $86.00 | 21,618.0000 | 17,757,000 | 9.48% | 0.01% |
| May 15, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 5873 | $86.01 | 23,882.0000 | 17,757,000 | 19.74% | 0.03% |
| Feb. 27, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | A | Employee Stock Option (right to buy) | 29272 | $0.00 | 29,272.0000 | 17,757,000 | 9999.99% | 0.16% |
| Feb. 27, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | A | Common Stock | 7208 | $0.00 | 28,631.0000 | 17,757,000 | 33.65% | 0.04% |
| Feb. 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 799 | $55.75 | 29,430.0000 | 17,757,000 | 2.79% | 0.00% |
| Feb. 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 140 | $57.22 | 29,570.0000 | 17,757,000 | 0.48% | 0.00% |
| Feb. 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Common Stock | 325 | $58.49 | 29,895.0000 | 17,757,000 | 1.10% | 0.00% |
| Feb. 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | S | Common Stock | 140 | $88.46 | 29,755.0000 | 17,757,000 | 0.47% | 0.00% |
| Feb. 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 799 | $0.00 | 2,869.0000 | 17,757,000 | 21.78% | 0.00% |
| Feb. 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 140 | $0.00 | 7,722.0000 | 17,757,000 | 1.78% | 0.00% |
| Feb. 28, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | M | Employee Stock Option (right to buy) | 325 | $0.00 | 1,607.0000 | 17,757,000 | 16.82% | 0.00% |
| Feb. 15, 2024 | LIGAND PHARMACEUTICALS INC | $LGND | Espinoza Octavio | Chief Financial Officer | F | Common Stock | 1479 | $74.65 | 21,423.0000 | 17,757,000 | 6.46% | 0.01% |